Katy Athersuch
Biographic Data
| ID | 9800939 |
|---|---|
| NAME | Katy Athersuch |
| GIVEN NAMES | Katy |
| FAMILY NAME | Athersuch |
| SIGNATURE | ATHERSUCH K |
| AFFILIATIONS | Médecins Sans Frontières |
| VERIFIED | No |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2022 |
| LATEST PUBLICATION YEAR | 2022 |
| H-INDEX | 0 |
Recently developed drugs for the treatment of drug-resistant tuberculosis
Two drugs with novel mechanisms of action, the diarylquinoline bedaquiline and the nitroimidazole delamanid—as well as pretomanid from the same class of drugs as delamanid—have recently become available to treat drug-resistant tuberculosis (DR-TB) after many decades of little innovation in the field of DR-TB treatment. Despite evidence of improved efficacy and reduced toxicity of multidrug regimens including the two agents, access to bedaquiline …
No prominent works on this page.
Recently developed drugs for the treatment of drug-resistant tuberculosis
Two drugs with novel mechanisms of action, the diarylquinoline bedaquiline and the nitroimidazole delamanid—as well as pretomanid from the same class of drugs as delamanid—have recently become available to treat drug-resistant tuberculosis (DR-TB) after many decades of little innovation in the field of DR-TB treatment. Despite evidence of improved efficacy and reduced toxicity of multidrug regimens including the two agents, access to bedaquiline …
Bedaquiline (1 work) · Business (1 work) · Clinical trial (1 work) · Drug (1 work) · Drug development (1 work) · Incentive (1 work) · Intensive care medicine (1 work) · Internal Medicine (1 work) · Medicine (1 work) · Mycobacterium tuberculosis (1 work)